These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34469756)

  • 1. Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.
    Lenda T; Ossowska K; Berghauzen-Maciejewska K; Matłoka M; Pieczykolan J; Wieczorek M; Konieczny J
    Eur J Pharmacol; 2021 Nov; 910():174460. PubMed ID: 34469756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
    Arakawa K; Yuge N; Maehara S
    Pharmacol Rep; 2020 Apr; 72(2):443-448. PubMed ID: 32144743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys.
    Beck G; Maehara S; Chang PL; Papa SM
    Mov Disord; 2018 May; 33(5):805-814. PubMed ID: 29508924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
    Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
    Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
    Sciaccaluga M; Mazzocchetti P; Bastioli G; Ghiglieri V; Cardinale A; Mosci P; Caccia C; Keywood C; Melloni E; Padoani G; Vailati S; Picconi B; Calabresi P; Tozzi A
    Neuropharmacology; 2020 Jun; 170():108024. PubMed ID: 32142791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
    Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C
    Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
    Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
    Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M
    Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium nitroprusside enhances stepping test performance and increases medium spiny neurons responsiveness to cortical inputs in a rat model of Levodopa-induced dyskinesias.
    Ribeiro DL; Guimarães RP; Bariotto-Dos-Santos K; Del Bel E; Padovan-Neto FE
    Eur J Neurosci; 2024 Apr; 59(7):1604-1620. PubMed ID: 38359910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
    Lundblad M; Andersson M; Winkler C; Kirik D; Wierup N; Cenci MA
    Eur J Neurosci; 2002 Jan; 15(1):120-32. PubMed ID: 11860512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.
    Masilamoni GJ; Sinon CG; Kochoian BA; Singh A; McRiner AJ; Leventhal L; Papa SM
    Neuropharmacology; 2022 Jul; 212():109060. PubMed ID: 35461880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.